Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families

Clinical Cancer Research

Volumn 17, Issue 7, 2011, Pages 1906-1914

  Yu, Kelly J ^a   Hsu, Wan Lun ^b,c   Pfeiffer, Ruth M ^a   Chiang, Chun Ju ^b,c   Wang, Cheng Ping ^d   Lou, Pei Jen ^d   Cheng, Yu Juen ^b   Gravitt, Patti ^e   Diehl, Scott R ^f   Goldstein, Alisa M ^a   Chen, Chien Jen ^b,c   Hildesheim, Allan ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c GENOMICS RESEARCH CENTER   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f RUTGERS SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBONUCLEASE; EPSTEIN BARR VIRUS ANTIBODY; EPSTEIN BARR VIRUS ANTIGEN 1; IMMUNOGLOBULIN A ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS CAPSID ANTIGEN;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CANCER INCIDENCE; CANCER RISK; CLINICAL ARTICLE; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MALE; NASOPHARYNX CARCINOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TAIWAN;

ADULT; AGED; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; CARCINOMA; DEOXYRIBONUCLEASES; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN A; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; ODDS RATIO; PROGNOSIS; RISK FACTORS; ROC CURVE;

EID: 79953331026     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1681     Document Type: Article

References (29)

1. McDermott AL, Dutt SN, Watkinson JC. The aetiology of nasopharyngeal carcinoma. Clin Otolaryngol 2001;26:82-92. (Pubitemid 32368223)
2. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000;343:481-92. (Pubitemid 30646489)
3. Hsu JL, Glaser SL. Epstein-Barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Oncog 2000;34:27-53. (Pubitemid 30227315)
4. De-The G, Lavoue MF, Muenz L. Differences in EBV antibody titres of patients with nasopharyngeal carcinoma originating from high, intermediate and low incidence areas. IARC Sci Publ 1978;471-81. (Pubitemid 9111622)
5. Mueller M, Evans A, Harris NL, Comstock GW, Jellum E, Magnus K, et al. Hodgkin's disease and Epstein-Barr virus-altered antibody pattern before diagnosis. N Engl J Med 1988;320:689-95.
6. Lennette ET, Winberg G, Yadav M, Enbald G, Klein G. Antibodies to LMP2A/2B in EBV-carrying malignancies. Eur J Cancer 1995;31:1875-8.
7. Xu J, Ahmad A, D'Addario M, Knafo L, Jones JF, Prasad U, et al. Analysis and significance of anti-latent membrane protein-1 antibodies in the sera of patients with EBV-associated diseases. J Immunol 2000;164:2815-22. (Pubitemid 30115517)
8. Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen CJ, et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 2001;345:1877-82.
9. Zeng Y, Zhang LG, Wu YC, Huang YS, Huang NQ, Li JY, et al. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou city, China. Int J Cancer 1985;36:545-7. (Pubitemid 16233512)
10. Pickard A, Chen CJ, Diehl SR, Liu MY, Cheng YJ, Hsu WL, et al. EBV seroreactivity among unaffected individuals within high-risk nasopharyngeal carcinoma families in Taiwan. Int J Cancer 2004;111:117-23. (Pubitemid 38859292)
11. Yang XR, Goldstein AM, Chen CJ, Rabkin CS, Chen JY, Cheng YJ, et al. Distribution of Epstein-Barr viral load in serum of individuals from nasopharyngeal carcinoma high-risk families in Taiwan. Int J Cancer 2006;118:780-4. (Pubitemid 43076031)
12. Yu KJ, Hsu WL, Chiang CJ, Cheng YJ, Pfeiffer RM, Diehl SR, et al. Cancer patterns in nasopharyngeal carcinoma multiplex families in Taiwan. Int J Cancer 2009;124:1622-5.
13. Henle G, Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976;17:1-7.
14. Ng WT, Choi CW, Lee MC, Law LY, Yau TK, Lee AW. Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong. Fam Cancer 2010;9:221-8.
15. Ji MF, Wang DK, Yu YL, Guo YQ, Liang JS, Cheng WM, et al. Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br J Cancer 2007;96:623-30.
16. Wong MM, Lye MS, Cheng HM, Sam CK. Epstein-Barr virus serology in the diagnosis of nasopharyngeal carcinoma. Asian Pac J Allergy Immunol 2005;23:65-7. (Pubitemid 40790090)
17. Ng WT, Yau TK, Yung RW, Sze WM, Tsang AH, Law AL, et al. Screening for family members of patients with nasopharyngeal carcinoma. Int J Cancer 2005;113:998-1001. (Pubitemid 40096880)
18. Zong YS, Sham JS, Ng MH, Ou XT, Guo YQ, Zheng SA, et al. Immunoglobulin a against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer 1992;69:3-7.
19. Fachiroh J, Schouten T, Hariwiyanto B, Paramita DK, Harijadi A, Haryana SM, et al. Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects. Infect Dis 2004;190:53-62. (Pubitemid 38858404)
20. van Grunsven WM, Nabbe A, Middeldorp JM. Identification and molecular characterization of two diagnostically relevant marker proteins of the Epstein-Barr virus capsid antigen complex. J Med Virol 1993;40:161-9. (Pubitemid 23169746)
21. Meij P, Vervoort MB, Aarbiou J, van Dissel P, Brink A, Bloemena E, et al. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases. J Infect Dis 1999;179;1108-15. (Pubitemid 29196489)
22. Tedeschi R, Foong YT, Cheng HM, et al. The disease association of the antibody response against the Epstein-Barr virus transactivator protein ZEBRA can be separated into different epitopes. J Gen Virol 1995;76:1393-400.
23. Cheng YC, Chen JY, Glaser R, Henle W. Frequency and levels of antibodies to Epstein-Barr virus specific DNase are elevated in patients with nasopharyngeal carcinoma. Proc Natl Acad Sci U S A 77:6162-5.
24. Bardy B, Morinet F, Perol Y. Occurrence of Epstein-Barr virus deoxyribonuclease enzyme activity-neutralizing antibodies. Intervirology 1989;30:36-43. (Pubitemid 19088935)
25. Stolzenberg MC, Debouze S, Ng M, Sham J, Choy D, Bouguermouh A, et al. Purified recombinant EBV deoxyribonuclease in serological diagnosis of nasopharyngeal carcinoma. Int J Cancer 1996;66:337-41. (Pubitemid 26166195)
26. Shimakage M, Ikegaman N, Chatani M, Yoshino K, Sato T. Serological follow-up study on the antibody levels to Epstein-Barr virus-determined nuclear antigen (EBNA) patients with nasopharyngeal carcinoma (NPC) after radiation therapy. Biken J 1987;30:45-52.
27. Foong YT, Cheng HM, Sam CK, Dillner J, Hinderer W, Prasad U. Serum and salivary IgA against a defined epitope of the Epstein-Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma. Int J Cancer 1990;45:1061-4. (Pubitemid 20201576)
28. Dardari R, Hinderer W, Lang D, Benider A, El Gueddari B, Joab I, et al. Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients: complementary test of ZEBRA protein and early antigen p54 and p138. J Clin Microbiol 2001;39:3164-70. (Pubitemid 32830309)
29. Chan KH, Gu YL, Ng F, Ng PS, Seto WH, Sham JS, et al. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. Int J Cancer 2003;105:706-9. (Pubitemid 36687741)